2Halushka MK, Fan JB, Bentley K, et al. Patterns of single-nucleotide polumorphisms in eandidats genes for hlood-pressure homeostasis [J ].Nat Genet, 1999,22(3) :239-247.
3Krynetski EY, Evans WE. Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine s-methy-ltransferase paradigm[J]. Pharm Res, 1999,16(3) :342-349.
4Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylationg agents[J]. N Engl J Med,2000,343 (19) : 1350-1354.
6Emilien G, Ponchon M, Caldas C. Impaet of genomics on drug discovery and clinical medicine[J]. QJM,2000,93(7) :391-423.
7Yue Q, Jen JC, Thwe MM, et al. De novo mutation in CACNAIA causedacetazolamide-responsive episodic at axia[J]. Am J Med Genet,1998,77(4) :298-301.
8Mehl B, Santell JP. Projecting future drug expenditures-2000[ J].Am J Health Syst Pharm,2000,57(2) : 129-138.
9Komarov PG, Komarova EA, Kondratov RV. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy[ J ]. Science,1999,285 (5434): L733-1737.
